Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Mario Eisenberger"'
Autor:
Mario Eisenberger
Publikováno v:
Revista Brasileira de Cancerologia, Vol 33, Iss 1 (2023)
In the United States, 1987 estimates of cancer incidence by site indicate that prostatic cancer is equal to lung cancer as the first in incidence in adult males. Over 90,000 new cases are diagnosed and between 25-30,000 patients die of this disease e
Externí odkaz:
https://doaj.org/article/2b5dd7b2b1834bdb880359e4361b19ee
Autor:
Alexander Meisel, Ronald de Wit, Stephane Oudard, Oliver Sartor, Frank Stenner-Liewen, Zhenming Shun, Meredith Foster, Ayse Ozatilgan, Mario Eisenberger, Johann S. de Bono
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background and purpose: Chemotherapy-induced neutropenia and neutrophil-to-lymphocyte ratio (NLR) are potentially useful prognostic markers in patients with metastatic castration-resistant prostate cancer (mCRPC). This post hoc analysis investigated
Externí odkaz:
https://doaj.org/article/64e2736141b249ca9f83a58bb38e988a
Autor:
Roche Kapoor, Matthew P. Deek, Riley McIntyre, Natasha Raman, Megan Kummerlowe, Iyah Chen, Matt Gaver, Hao Wang, Sam Denmeade, Tamara Lotan, Channing Paller, Mark Markowski, Michael Carducci, Mario Eisenberger, Tomasz M. Beer, Daniel Y. Song, Theodore L. DeWeese, Jason W. Hearn, Stephen Greco, Curtiland DeVille, Neil B. Desai, Elisabeth I. Heath, Stanley Liauw, Daniel E. Spratt, Arthur Y. Hung, Emmanuel S. Antonarakis, Phuoc T. Tran
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background In men with a rising PSA following radical prostatectomy, salvage radiation therapy (SRT) offers a second chance for cure. Hormonal therapy can be combined with SRT in order to increase prostate tumor control, albeit with associat
Externí odkaz:
https://doaj.org/article/2eb48a9b5d9f4772a8b098572c4cd10f
Autor:
Nicolas Delanoy, Debbie Robbrecht, Mario Eisenberger, Oliver Sartor, Ronald de Wit, Florence Mercier, Christine Geffriaud-Ricouard, Johann de Bono, Stéphane Oudard
Publikováno v:
Cancers, Vol 13, Iss 6, p 1284 (2021)
Background: In the PROSELICA phase III trial (NCT01308580), cabazitaxel 20 mg/m2 (CABA20) was non-inferior to cabazitaxel 25 mg/m2 (CABA25) in mCRPC patients previously treated with docetaxel (DOC). The present post hoc analysis evaluates how the typ
Externí odkaz:
https://doaj.org/article/ac4e5d2165a8497890532891f5567c16
Autor:
Noura Radwan, Ryan Phillips, Ashley Ross, Steven P. Rowe, Michael A. Gorin, Emmanuel S. Antonarakis, Curtiland Deville, Stephen Greco, Samuel Denmeade, Channing Paller, Daniel Y. Song, Maximilian Diehn, Hao Wang, Michael Carducci, Kenneth J. Pienta, Martin G. Pomper, Theodore L. DeWeese, Adam Dicker, Mario Eisenberger, Phuoc T. Tran
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background We describe a randomized, non-blinded Phase II interventional study to assess the safety and efficacy of stereotactic ablative radiotherapy (SABR) for hormone-sensitive oligometastatic prostate adenocarcinoma, and to describe the
Externí odkaz:
https://doaj.org/article/9cb0da5a00494bb597a47c7f7df97836
Autor:
Phuoc T. Tran, Kathryn Lowe, Hua-Ling Tsai, Daniel Y. Song, Arthur Y. Hung, Jason W.D. Hearn, Steven Miller, James A. Proudfoot, Matthew P. Deek, Ryan Phillips, Tamara Lotan, Channing J. Paller, Catherine H. Marshall, Mark Markowski, Shirl Dipasquale, Samuel Denmeade, Michael Carducci, Mario Eisenberger, Theodore L. DeWeese, Matthew Orton, Curtiland Deville, Elai Davicioni, Stanley L. Liauw, Elisabeth I. Heath, Stephen Greco, Neil B. Desai, Daniel E. Spratt, Felix Feng, Hao Wang, Tomasz M. Beer, Emmanuel S. Antonarakis
Publikováno v:
Journal of Clinical Oncology. 41:1307-1317
PURPOSE We sought to investigate whether enzalutamide (ENZA), without concurrent androgen deprivation therapy, increases freedom from prostate-specific antigen (PSA) progression (FFPP) when combined with salvage radiation therapy (SRT) in men with re
Autor:
Mario Eisenberger, Ian F. Tannock, Ronald de Wit, Yi-Chun Ou Yang, Elizabeth S. Garrett-Mayer, Andrew J. Armstrong
Supplementary Figure S1; Supplementary Tables S1-S3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::524eccd43a27e1ce2abbef69698a88ad
https://doi.org/10.1158/1078-0432.22439601.v1
https://doi.org/10.1158/1078-0432.22439601.v1
Purpose: We sought to evaluate predictors of overall survival following progression after systemic chemotherapy in men with metastatic castration-resistant prostate cancer.Experimental Design: For our study population, we used the TAX327 multicenter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52eb6fd6aca2b177b8ab384b590063ae
https://doi.org/10.1158/1078-0432.c.6520833.v1
https://doi.org/10.1158/1078-0432.c.6520833.v1
Autor:
Mario Eisenberger, Ian F. Tannock, Ronald de Wit, Yi-Chun Ou Yang, Elizabeth S. Garrett-Mayer, Andrew J. Armstrong
Purpose: To develop a prognostic model and nomogram using baseline clinical variables to predict death among men with metastatic hormone-refractory prostate cancer (HRPC).Experimental Design: TAX327 was a clinical trial that randomized 1,006 men with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67b9be2b062f6e8ce8751a65616c015a
https://doi.org/10.1158/1078-0432.c.6517041
https://doi.org/10.1158/1078-0432.c.6517041
Supplementary Data from Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81615383318281fbbfaf59ac45e6decb
https://doi.org/10.1158/1078-0432.22446690.v1
https://doi.org/10.1158/1078-0432.22446690.v1